MX2020002432A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2020002432A
MX2020002432A MX2020002432A MX2020002432A MX2020002432A MX 2020002432 A MX2020002432 A MX 2020002432A MX 2020002432 A MX2020002432 A MX 2020002432A MX 2020002432 A MX2020002432 A MX 2020002432A MX 2020002432 A MX2020002432 A MX 2020002432A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral administration
fxr
farnesoid
octan
Prior art date
Application number
MX2020002432A
Other languages
English (en)
Inventor
Geoffrey Gogniat
Claus Dieter Bischoff
Sonali Bose
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020002432A publication Critical patent/MX2020002432A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para administración oral que comprende un agonista del receptor farnesoide X (FXR) no biliar, ácido 2-[(1R,3R,5S)-3-({5-ciclopropi lo-3-[2-(trifluorometoxi)fenil]-1,2-oxazol-4-il}metoxi)-8-azabici clo[3.2.1]octan-8-iI]-4-fluoro-1,3-benzotiazol-6-carboxílico, o una de sus sales farmacéuticamente aceptables, y por lo menos un excipiente lípido; a una cápsula para administración oral que comprende dicha composición farmacéutica; al uso de dicha composición farmacéutica para el tratamiento de una afección o un trastorno mediado por FXR; y a un proceso para la preparación de dicha composición farmacéutica.
MX2020002432A 2017-09-12 2018-09-11 Composicion farmaceutica. MX2020002432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557298P 2017-09-12 2017-09-12
PCT/IB2018/056904 WO2019053581A1 (en) 2017-09-12 2018-09-11 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
MX2020002432A true MX2020002432A (es) 2020-07-13

Family

ID=63686041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002432A MX2020002432A (es) 2017-09-12 2018-09-11 Composicion farmaceutica.

Country Status (15)

Country Link
US (2) US11207313B2 (es)
EP (1) EP3681485A1 (es)
JP (1) JP2020533297A (es)
KR (1) KR20200052280A (es)
CN (1) CN111093637A (es)
AR (1) AR114930A1 (es)
AU (1) AU2018332191B2 (es)
BR (1) BR112020004663A2 (es)
CA (1) CA3072559A1 (es)
CL (1) CL2020000601A1 (es)
IL (1) IL272419A (es)
MX (1) MX2020002432A (es)
RU (1) RU2020111980A (es)
TW (1) TW201919626A (es)
WO (1) WO2019053581A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111356458A (zh) * 2017-11-30 2020-06-30 诺华股份有限公司 用于治疗肝疾病的fxr激动剂
WO2021104022A1 (zh) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
WO2021104021A1 (zh) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
WO2021233461A1 (zh) * 2020-05-22 2021-11-25 苏州晶云药物科技股份有限公司 苯并噻唑类化合物的新晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252670A1 (en) 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
WO2011054087A1 (en) * 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
HK1257648A1 (zh) 2016-02-22 2019-10-25 Novartis Ag Fxr促效剂之使用方法
SI3419624T1 (sl) 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas

Also Published As

Publication number Publication date
US11207313B2 (en) 2021-12-28
KR20200052280A (ko) 2020-05-14
JP2020533297A (ja) 2020-11-19
CL2020000601A1 (es) 2020-09-11
US20190076418A1 (en) 2019-03-14
WO2019053581A1 (en) 2019-03-21
AR114930A1 (es) 2020-11-11
EP3681485A1 (en) 2020-07-22
BR112020004663A2 (pt) 2020-09-15
TW201919626A (zh) 2019-06-01
US20220071983A1 (en) 2022-03-10
RU2020111980A (ru) 2021-10-13
IL272419A (en) 2020-03-31
CA3072559A1 (en) 2019-03-21
CN111093637A (zh) 2020-05-01
RU2020111980A3 (es) 2021-11-23
AU2018332191A1 (en) 2020-02-20
AU2018332191B2 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
ZA201608614B (en) Solid oral pharmaceutical compositions for isoxazoline compounds
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
JP2017505293A5 (es)
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MX388643B (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
AR114930A1 (es) Composición farmacéutica
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
MX2022009032A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
PH12017501831A1 (en) Pharmaceutical compositions for oral administration
MX393779B (es) Orvepitant para el tratamiento de la tos cronica
EA036542B9 (ru) Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
JP2016514688A5 (es)
BR112022007468A2 (pt) Composições farmacêuticas compreendendo (s)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona e métodos para usar as mesmas
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
MY193041A (en) Novel fused imidazobenzothiazole compounds
EP4021920A4 (en) IMPROVED PROCESS FOR PRODUCTION OF ETELCALCETIDE HYDROCHLORIDE
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
NZ722727A (en) 1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
ZA202101279B (en) A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride
MX2014005960A (es) Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2.